Biotech News

Neuronetics Announces Selected Preliminary Unaudited Fourth Quarter and Full Year 2025 Financial Results

Neuronetics (STIM)Neuronetics2026-06-25 13:46 ESTEarnings

All values provided represent preliminary unaudited results Fourth quarter 2025 revenue of $41.8 million, representing 86% year-over-year growth on an as reported basis and 23% year-over-year growth on an adjusted pro forma basis Full year 2025 revenue of $149.2 million, representing 99%

Open original release

Related news

STIMNeuronetics2026-07-06 12:30 EST

Neuronetics to Participate in a Panel Discussion at B. Riley Securities' Mind, Muscle & Vision Summit on July 16, 2026

STIMNeuronetics2026-06-25 13:46 EST

Neuronetics Appoints Robert Greene as Senior Vice President Sales

STIMNeuronetics2026-06-25 13:46 EST

Neuronetics Highlights Continued Advancements in TMS Research at CTMSS 2026

STIMNeuronetics2026-06-25 13:46 EST

Neuronetics and ANT Neuro Announce Strategic Collaboration to Integrate Neuronavigation with NeuroStar TMS Treatment

STIMNeuronetics2026-06-25 13:46 EST

Neuronetics to Report Fourth Quarter 2025 Financial and Operating Results and Host Conference Call

STIMNeuronetics2026-06-25 13:46 EST

Neuronetics Appoints Dan Reuvers as President and Chief Executive Officer

STIMNeuronetics2026-06-25 13:46 EST

Neuronetics Reports Fourth Quarter and Full Year 2025 Financial and Operating Results

STIMNeuronetics2026-06-25 13:46 EST

Neuronetics Announces Chief Financial Officer Transition

STIMNeuronetics2026-06-25 13:46 EST

Neuronetics Comments on Letter from Pointillist Family Office

STIMNeuronetics2026-06-25 13:46 EST

Optum/United Healthcare/United Behavioral Health Expands NeuroStar® TMS Coverage to Include Psychiatric Mental Health Nurse Practitioners

View all latest news

Neuronetics

Neuronetics is a biopharmaceutical company focused on advancing a pipeline of therapeutic programs. Investors usually track how clinical data, regulatory milestones, and launch execution change the story over time.

Recent company news

STIMZimmer Biomet2026-07-14 12:13 EST

Zimmer Biomet Names Chintan Desai President of Asia Pacific Region

STIMZimmer Biomet2026-07-13 12:14 EST

Zimmer Biomet Announces Webcast and Conference Call of Second Quarter 2026 Financial Results

STIMBMYBristol-Myers Squibb Company2026-07-13 10:59 EST

U.S. Food and Drug Administration Accepts Bristol Myers Squibb's New Drug Application for Mezigdomide in Patients with Relapsed or Refractory Multiple Myeloma

STIMGSK plc2026-07-13 07:00 EST

Jemperli (dostarlimab) achieves sustained clinical complete responses in dMMR/MSI-H locally advanced rectal cancer

STIMMerck2026-07-10 19:01 EST

FDA Approves KEYTRUDA® (pembrolizumab) and KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph), Each With Padcev® (enfortumab vedotin-ejfv), as Treatment Before and After Surgery for Adults With Muscle-Invasive Bladder Cancer (MIBC)

Stock data

Close: 1.79 USD
Market cap: 122.47M USD
Exchange: NASDAQ
Sector: Biotechnology
Location: United States